Pelabresib
Phase 3Recruiting 0 views this week 0 watching⚡ Active
Interest: 47/100
47
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Hematologic Malignancy
Conditions
Hematologic Malignancy, Solid Tumor, Advanced Malignancies
Trial Timeline
Aug 13, 2024 → Jun 30, 2027
NCT ID
NCT06401356About Pelabresib
Pelabresib is a phase 3 stage product being developed by Novartis for Hematologic Malignancy. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06401356. Target conditions include Hematologic Malignancy, Solid Tumor, Advanced Malignancies.
What happened to similar drugs?
1 of 4 similar drugs in Hematologic Malignancy were approved
Approved (1) Terminated (0) Active (3)
Hype Score Breakdown
Clinical
17
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07422610 | Phase 1 | Recruiting |
| NCT06401356 | Phase 3 | Recruiting |
Competing Products
20 competing products in Hematologic Malignancy
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| 120 mg LY2784544 | Eli Lilly | Phase 2 | 39 |
| RLYB116 for Injection | Rallybio | Phase 1 | 19 |
| DS3790a + Combination drug + Combination drug | Daiichi Sankyo | Phase 1/2 | 39 |
| Isavuconazole | Astellas Pharma | Phase 2 | 35 |
| isavuconazonium sulfate - intravenous + isavuconazonium sulfate - oral | Astellas Pharma | Phase 1 | 29 |
| DSP-5336 + [14C]-DSP-5336 | Sumitomo Pharma | Phase 1 | 36 |
| BBI608 + Dexamethasone + Bortezomib + Imatinib + Ibrutinib | Sumitomo Pharma | Phase 1 | 29 |
| Venetoclax + ethinyl estradiol/levonorgestrel | AbbVie | Phase 1 | 36 |
| ABT-888 + Temozolomide | AbbVie | Phase 1 | 29 |
| ABBV-101 | AbbVie | Phase 1 | 36 |
| elotuzumab + lenalidomide + dexamethasone oral + dexamethasone injection | AbbVie | Phase 2 | 35 |
| Capivasertib + Rabeprazole | AstraZeneca | Phase 1 | 29 |
| AZD9829 + AZD9829 | AstraZeneca | Phase 1/2 | 36 |
| ridaforolimus | Merck | Phase 2 | 35 |
| Pembrolizumab/vibostolimab coformulation | Merck | Phase 2 | 35 |
| Nemtabrutinib | Merck | Phase 1 | 29 |
| Ondansetron + Aprepitant | Merck | Phase 2 | 35 |
| Nemtabrutinib | Merck | Phase 2 | 42 |
| ARQ 621 | Merck | Phase 1 | 29 |
| Nemtabrutinib | Merck | Phase 1 | 33 |